Evidence-based cost-benefit analysis of Creatinine.
Creatinine is a waste product from muscle metabolism and is commonly used as a biomarker for kidney function. Elevated serum creatinine levels can indicate impaired kidney function, particularly in the context of acute kidney injury (AKI). However, creatinine levels can be delayed in reflecting true kidney function changes, especially in critically ill patients. Emerging biomarkers may provide more timely and sensitive detection of AKI, highlighting the need for comprehensive kidney function assessment.
Individuals at risk for kidney dysfunction, including critically ill patients, those with chronic kidney disease, or individuals undergoing procedures that may impact kidney function. Healthcare providers monitoring kidney health in patients are also key users of creatinine measurements.
While creatinine is a valuable marker, it has limitations, such as being influenced by muscle mass, diet, and hydration status. It may not accurately reflect kidney function in all populations, particularly in the elderly or those with low muscle mass. Additionally, healthcare providers should consider the use of emerging biomarkers for a more comprehensive assessment of kidney health. Regular monitoring and clinical judgment are essential in interpreting creatinine levels.
Compare other supplements by cost and evidence
Educational and research purposes only. Always consult a healthcare professional before starting any supplement regimen. ROI is modelled at $100,000 per quality-adjusted life year; see the methodology.